![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Physiology, Heart and Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research, University of Toronto, Toronto, Ontario, Canada (S.G., A.A., S.P.H.); Department of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston, Houston, Texas (S.S., C.W.D.); and Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri (K.J.B.)
The regulator of G-protein signaling (RGS2) contains a characteristic RGS domain flanked by short amino and carboxyl terminal sequences. The RGS domain mediates inhibition of G
q and Gi signaling, whereas the amino terminal domain (NTD) directs interaction with adenylyl cyclases, G-protein-coupled receptors, and other signaling partners. Here, we identify a set of novel RGS2 protein products that differ with respect to their amino terminal architecture and functional characteristics. An RGS2 expression reporter cassette revealed four distinct open reading frames (ORFs) that can be expressed from the RGS2 NTD. We hypothesized that alternative translation initiation from four AUG codons corresponding to amino acid positions 1, 5, 16, and 33 could produce the observed RGS2 expression profile. Selective disruption of each AUG confirmed that alternate sites of translation initiation accounted for each of the observed products. Proteins derived from ORFs 1 to 4 showed no difference in Gq inhibitory potential or recruitment from the nucleus in response to Gq signaling. By contrast, RGS2 products initiating from methionines at positions 16 (ORF3) and 33 (ORF4) were impaired as inhibitors of type V adenylyl cyclase (ACV) compared with full-length RGS2. We predicted that regulation of the RGS2 expression profile would allow cells to adapt to changing signaling conditions. Consistent with this model, activation of Gs/ACV but not Gq signaling increased the relative abundance of the full-length RGS2 protein, suggesting that alternative translation initiation of RGS2 is part of a novel negative feedback control pathway for adenylyl cyclase signaling.
Received for publication March 22, 2007.
Accepted for publication September 10, 2007.
Address correspondence to: Dr. Scott P. Heximer, Canada Research Chair in Cardiovascular Physiology, University of Toronto, 1 King's College Circle, Toronto, Ontario M5S 1A8. E-mail: scott.heximer{at}utoronto.ca
This article has been cited by other articles:
|
|
 |
|
  C. H. Nguyen, H. Ming, P. Zhao, L. Hugendubler, R. Gros, S. R. Kimball, and P. Chidiac Translational control by RGS2 J. Cell Biol., September 7, 2009; 186(5): 755 - 765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lelonek, T. Pietrucha, M. Matyjaszczyk, and J. H. Goch A novel approach to syncopal patients: association analysis of polymorphisms in G-protein genes and tilt outcome Europace, January 1, 2009; 11(1): 89 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Yau, N. Sethakorn, S. Taurin, S. Kregel, N. Sandbo, B. Camoretti-Mercado, A. I. Sperling, and N. O. Dulin Regulation of Smad-Mediated Gene Transcription by RGS3 Mol. Pharmacol., May 1, 2008; 73(5): 1356 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gu, S. Tirgari, and S. P. Heximer The RGS2 Gene Product from a Candidate Hypertension Allele Shows Decreased Plasma Membrane Association and Inhibition of Gq Mol. Pharmacol., April 1, 2008; 73(4): 1037 - 1043. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
